Related Articles
BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia
TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis
AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B
Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML
BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML